1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells

被引:67
作者
Chintharlapalli, S
Smith, R
Samudio, I
Zhang, W
Safe, S
机构
[1] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA
[2] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA
[3] Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA
[4] Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA
[5] Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF(3)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC(6)H(5)) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines. Rosiglitazone also induces transactivation in these cell lines and inhibited growth of HT-29 cells, which express wild-type PPARgamma but not HCT-15 cells, which express mutant (K422Q) PPARgamma. In contrast, DIM-C-pPhCF(3), DIM-C-pPhtBu, and DIM-C-pPhC(6)H(5) inhibited growth of both HT-29 and HCT-15 cells with IC50 values ranging from 1 to 10 mumol/L. Rosiglitazone and diindolylmethane (DIM) analogues did not affect expression of cyclin D1, p21, or p27 protein levels or apoptosis in HCT-15 or HT-29 cells but induced keratin 18 in both cell lines. However, rosiglitazone induced caveolins 1 and 2 in HT-29 but not HCT-15 cells, whereas these differentiation markers were induced by DIM-C-pPhCF3 and DIM-C-pPhC6H5 in both cell lines. Because overexpression of caveolin 1 is known to suppress colon cancer cell and tumor growth, the growth inhibitory effects of rosiglitazone and the DIM compounds are associated with PPARgamma-dependent induction of caveolins.
引用
收藏
页码:5994 / 6001
页数:8
相关论文
共 24 条
[1]  
Bender FC, 2000, CANCER RES, V60, P5870
[2]   Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells [J].
Brockman, JA ;
Gupta, RA ;
DuBois, RN .
GASTROENTEROLOGY, 1998, 115 (05) :1049-1055
[3]   Peroxisome proliferator-activated receptor-γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells [J].
Burgermeister, E ;
Tencer, L ;
Liscovitch, M .
ONCOGENE, 2003, 22 (25) :3888-3900
[4]  
Chang TH, 2000, CANCER RES, V60, P1129
[5]   Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice [J].
Elstner, E ;
Müller, C ;
Koshizuka, K ;
Williamson, EA ;
Park, D ;
Asou, H ;
Shintaku, P ;
Said, JW ;
Heber, D ;
Koeffler, HP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8806-8811
[6]   APIC-dependent suppression of colon carcinogenesis by PPARγ [J].
Girnun, GD ;
Smith, WM ;
Drori, S ;
Sarraf, P ;
Mueller, E ;
Eng, C ;
Nambiar, P ;
Rosenberg, DW ;
Bronson, RT ;
Edelmann, W ;
Kucherlapati, R ;
Gonzalez, FJ ;
Spiegelman, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13771-13776
[7]   Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells [J].
Gupta, RA ;
Brockman, JA ;
Sarraf, P ;
Willson, TM ;
DuBois, RN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (32) :29681-29687
[8]   Peroxisome proliferator-activated receptor γ-mediated differentiation -: A mutation in colon cancer cells reveals divergent and cell type-specific mechanisms [J].
Gupta, RA ;
Sarraf, P ;
Mueller, E ;
Brockman, JA ;
Prusakiewicz, JJ ;
Eng, C ;
Willson, TM ;
DuBois, RN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (25) :22669-22677
[9]  
Ikezoe T, 2001, CANCER RES, V61, P5307
[10]   Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone [J].
Kato, M ;
Kusumi, T ;
Tsuchida, S ;
Tanaka, M ;
Sasaki, M ;
Kudo, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (02) :73-79